FDA Expands CF Drug Kalydeco to Children as Young as Age 1 Year FDA Expands CF Drug Kalydeco to Children as Young as Age 1 Year

The drug is indicated for children as young as 12 months with at least one mutation in the CFTR gene that is responsive to the drug, as determined from clinical or in vitro assay data.FDA Approvals

Source: Medscape Medical News Headlines - August 17, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news